Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Consensus for Nonmelanoma Skin Cancer Treatment, Part II
Arielle N.B. Kauvar, Christopher J. Arpey, George J. Hruza, et al.
Dermatologic Surgery (2015) Vol. 41, Iss. 11, pp. 1214-1240
Closed Access | Times Cited: 112

Showing 1-25 of 112 citing articles:

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma
Michael R. Migden, Danny Rischin, Chrysalyne D. Schmults, et al.
New England Journal of Medicine (2018) Vol. 379, Iss. 4, pp. 341-351
Open Access | Times Cited: 1188
Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma
Glenn J. Hanna, Harita Dharanesswaran, Anita Giobbie‐Hurder, et al.
Journal of Clinical Oncology (2024) Vol. 42, Iss. 9, pp. 1021-1030
Open Access | Times Cited: 26
Updates on the Management of Non-Melanoma Skin Cancer (NMSC)
Artur Fahradyan, Anna C. Howell, Erik M. Wolfswinkel, et al.
Healthcare (2017) Vol. 5, Iss. 4, pp. 82-82
Open Access | Times Cited: 167
Mohs micrographic surgery: a review of indications, technique, outcomes, and considerations
Guilherme Canho Bittner, Felipe B. Cerci, Elisa Mayumi Kubo, et al.
Anais Brasileiros de Dermatologia (2021) Vol. 96, Iss. 3, pp. 263-277
Open Access | Times Cited: 79
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol
Karlijn Verkerk, Birgit S. Geurts, Laurien J. Zeverijn, et al.
The Lancet Regional Health - Europe (2024) Vol. 39, pp. 100875-100875
Open Access | Times Cited: 13
Cutaneous Squamous Cell Carcinoma: An Updated Review
Rina Jiang, Mike Fritz, Syril Keena T. Que
Cancers (2024) Vol. 16, Iss. 10, pp. 1800-1800
Open Access | Times Cited: 8
Validating 4 Staging Systems for Cutaneous Squamous Cell Carcinoma Using Population-Based Data
Ingrid Roscher, Ragnhild Sørum Falk, Linda Vos, et al.
JAMA Dermatology (2018) Vol. 154, Iss. 4, pp. 428-428
Open Access | Times Cited: 75
Non-invasive diagnostic techniques in the diagnosis of squamous cell carcinoma
Olga Warszawik‐Hendzel, Małgorzata Olszewska, Małgorzata Maj, et al.
Journal of Dermatological Case Reports (2015) Vol. 9, Iss. 4
Open Access | Times Cited: 71
Cemiplimab-rwlc as first and only treatment for advanced cutaneous squamous cell carcinoma
Saqib Ahmed, Erik Petersen, Ravi Patel, et al.
Expert Review of Clinical Pharmacology (2019) Vol. 12, Iss. 10, pp. 947-951
Closed Access | Times Cited: 66
Association of Immunosuppression With Outcomes of Patients With Cutaneous Squamous Cell Carcinoma of the Head and Neck
Samantha Tam, Christopher M. K. L. Yao, Moran Amit, et al.
JAMA Otolaryngology–Head & Neck Surgery (2019) Vol. 146, Iss. 2, pp. 128-128
Open Access | Times Cited: 59
Programmed cell death protein 1 inhibitors in advanced cutaneous squamous cell carcinoma: real-world data of a retrospective, multicenter study
Martin Salzmann, Ulrike Leiter, Carmen Loquai, et al.
European Journal of Cancer (2020) Vol. 138, pp. 125-132
Closed Access | Times Cited: 57
Mohs Micrographic Surgery
Emily Wong, Eileen Axibal, Mariah Brown
Facial Plastic Surgery Clinics of North America (2018) Vol. 27, Iss. 1, pp. 15-34
Closed Access | Times Cited: 54
Nonsurgical treatment of skin cancer with local delivery of bioadhesive nanoparticles
Jamie K. Hu, Hee‐Won Suh, Munibah Qureshi, et al.
Proceedings of the National Academy of Sciences (2021) Vol. 118, Iss. 7
Open Access | Times Cited: 37
A phase 2 open-label study of cemiplimab in patients with advanced cutaneous squamous cell carcinoma (EMPOWER-CSCC-1): Final long-term analysis of Groups 1, 2, and 3, and primary analysis of fixed-dose treatment Group 6
Brett Hughes, Alexander Guminski, Samantha Bowyer, et al.
Journal of the American Academy of Dermatology (2024) Vol. 92, Iss. 1, pp. 68-77
Closed Access | Times Cited: 5
Genome-wide meta-analysis identifies eight new susceptibility loci for cutaneous squamous cell carcinoma
Kavita Y. Sarin, Yuan Lin, Roxana Daneshjou, et al.
Nature Communications (2020) Vol. 11, Iss. 1
Open Access | Times Cited: 38
CASE (CemiplimAb-rwlc Survivorship and Epidemiology) study in advanced cutaneous squamous cell carcinoma
Michael R. Migden, Sunandana Chandra, Guilherme Rabinowits, et al.
Future Oncology (2020) Vol. 16, Iss. 4, pp. 11-19
Open Access | Times Cited: 33
Non-melanoma skin cancer treated with hypofractionated 192—Ir contact brachitherapy: a single institution series
E. Ciurlia, Bianca Santo, Marta Barba, et al.
Frontiers in Oncology (2025) Vol. 14
Open Access
Immunotherapy followed by cetuximab in locally advanced/metastatic cutaneous squamous cell carcinomas: the I-TACKLE trial
Paolo Bossi, Andrea Alberti, Cristiana Bergamini, et al.
European Journal of Cancer (2025), pp. 115379-115379
Closed Access
Current Efficacy, Safety and Survival Outcomes of Cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma: A Systematic Review and Meta-analysis
Srivatsa Surya Vasudevan, Tanisha Patel, John DiGiovanni, et al.
Journal of Investigative Dermatology (2025)
Closed Access
Comparison of electronic brachytherapy and Mohs micrographic surgery for the treatment of early-stage non-melanoma skin cancer: a matched pair cohort study
Rakesh Patel, Robert Strimling, Stephen Doggett, et al.
Journal of Contemporary Brachytherapy (2017) Vol. 4, pp. 338-344
Open Access | Times Cited: 34
Nonsurgical Treatments for Nonmelanoma Skin Cancer
Alexandra Collins, Jessica A. Savas, Laura Doerfler
Dermatologic Clinics (2019) Vol. 37, Iss. 4, pp. 435-441
Closed Access | Times Cited: 33
Immune Checkpoint Blockade in Advanced Cutaneous Squamous Cell Carcinoma: What Do We Currently Know in 2020?
Anja Wessely, Theresa Steeb, Ulrike Leiter, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 23, pp. 9300-9300
Open Access | Times Cited: 29
Basics of Confocal Microscopy and the Complexity of Diagnosing Skin Tumors
Syril Keena T. Que, Jane M. Grant‐Kels, Caterina Longo, et al.
Dermatologic Clinics (2016) Vol. 34, Iss. 4, pp. 367-375
Closed Access | Times Cited: 29
Assessing the Value of Cemiplimab for Adults With Advanced Cutaneous Squamous Cell Carcinoma: A Cost-Effectiveness Analysis
Gerasimos Konidaris, E. Paul, Andreas Kuznik, et al.
Value in Health (2021) Vol. 24, Iss. 3, pp. 377-387
Open Access | Times Cited: 23
First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma – A real-world experience from Israel
Itamar Averbuch, Saeed Salman, Noa Shtamper, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 8
Page 1 - Next Page

Scroll to top